141 related articles for article (PubMed ID: 26536179)
1. From Bone Cell Biology to Novel Therapies of Osteoporosis.
Hofbauer LC
Drug Res (Stuttg); 2015 Nov; 65 Suppl 1():S14-5. PubMed ID: 26536179
[No Abstract] [Full Text] [Related]
2. Cathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis?
Chapurlat R
Joint Bone Spine; 2016 May; 83(3):254-6. PubMed ID: 26919802
[No Abstract] [Full Text] [Related]
3. Two pioneering osteoporosis drugs finally approach approval.
Garber K
Nat Rev Drug Discov; 2016 Jun; 15(7):445-6. PubMed ID: 27357010
[No Abstract] [Full Text] [Related]
4. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
5. [Effect on bone structure and strength by novel anti-osteoporotic agents].
Sone T
Clin Calcium; 2013 Jul; 23(7):1021-6. PubMed ID: 23811591
[TBL] [Abstract][Full Text] [Related]
6. [Denosumab: Lifetime treatment of osteoporosis?].
Laroche M
Presse Med; 2016 Jan; 45(1):4-6. PubMed ID: 26880310
[No Abstract] [Full Text] [Related]
7. Bone Histomorphometry in an Osteoporotic Hemodialysis Patient Treated With Denosumab.
Ibuki Y; Hukuda T; Tabata S; Ito A
Ther Apher Dial; 2018 Jun; 22(3):302-304. PubMed ID: 28594111
[No Abstract] [Full Text] [Related]
8. New therapeutics for osteoporosis.
Ng KW; Martin TJ
Curr Opin Pharmacol; 2014 Jun; 16():58-63. PubMed ID: 24699340
[TBL] [Abstract][Full Text] [Related]
9. [Newly developed drugs to improve bone strength].
Hagino H
Clin Calcium; 2016 Jan; 26(1):99-105. PubMed ID: 26728536
[TBL] [Abstract][Full Text] [Related]
10. [Effects of antiresorptive therapy on the structural and material properties of bone strength].
Kishimoto H
Clin Calcium; 2016 Jan; 26(1):107-15. PubMed ID: 26728537
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of bone quality. Drug developments for restoring bone mass and quality in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2008 Mar; 18(3):374-80. PubMed ID: 18310826
[TBL] [Abstract][Full Text] [Related]
12. Denosumab after 8 years.
Reid IR
Osteoporos Int; 2015 Dec; 26(12):2759-61. PubMed ID: 26475285
[No Abstract] [Full Text] [Related]
13. [Update and perspectives of anabolic therapies for osteoporosis].
Endo I; Matsumoto T
Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
[TBL] [Abstract][Full Text] [Related]
14. Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis.
Papapoulos SE
Nat Rev Endocrinol; 2015 Feb; 11(2):69-70. PubMed ID: 25488486
[No Abstract] [Full Text] [Related]
15. Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis.
Robinson MK; Caminis J; Brunkow ME
Drug Discov Today; 2013 Jul; 18(13-14):637-43. PubMed ID: 23579167
[TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
17. On the horizon: better bone-building drugs?
Mayo Clin Health Lett; 2014 Dec; 32(12):4. PubMed ID: 26087525
[No Abstract] [Full Text] [Related]
18. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
Soen S
Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
[TBL] [Abstract][Full Text] [Related]
19. Merck &Co. drops osteoporosis drug odanacatib.
Mullard A
Nat Rev Drug Discov; 2016 Sep; 15(10):669. PubMed ID: 27681784
[No Abstract] [Full Text] [Related]
20. Pharmacological diversity among drugs that inhibit bone resorption.
Russell RG
Curr Opin Pharmacol; 2015 Jun; 22():115-30. PubMed ID: 26048735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
